(Q44276981)

English

Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States

scientific article published on 6 May 2008

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

United States of America

0 references

attenuated vaccine

1 reference

based on heuristic

inferred from title

influenza vaccine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert B Belshe

3

object named as

Robert B Belshe

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

author name string

Bryan R Luce

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Kristin L Nichol

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Kevin D Frick

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Su Xia Li

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Audra Boscoe

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Matthew D Rousculp

7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Parthiv J Mahadevia

8

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

language of work or name

0 references

publication date

6 May 2008

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

2841-2848

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Health impact of influenza in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Mortality associated with influenza and respiratory syncytial virus in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Estimating influenza hospitalizations among children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

The underrecognized burden of influenza in young children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Potential cost savings attributable to influenza vaccination of school-aged children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Patterns of Shedding of Myxoviruses and Paramyxoviruses in Children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

The Japanese experience with vaccinating schoolchildren against influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Live attenuated versus inactivated influenza vaccine in infants and young children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Economic impact of influenza vaccination in preschool children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Clinical and economic impact of influenza vaccination on healthy children aged 2–5 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

An economic analysis of annual influenza vaccination of children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Household-based costs and benefits of vaccinating healthy children in daycare against influenza virus: results from a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Health benefits, risks, and cost-effectiveness of influenza vaccination of children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Influenza-Associated Deaths among Children in the United States, 2003–2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

The cost of giving childhood vaccinations: differences among provider types

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

A respiratory therapist-directed protocol for managing inpatients with asthma and COPD incorporating a long-acting bronchodilator

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Resource costs for asthma-related care among pediatric patients in managed care

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

A study of influenza and influenza-related complications among children in a large US health insurance plan database

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Epidemiology, Complications, and Cost of Hospitalization in Children With Laboratory-Confirmed Influenza Infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Cost-effectiveness of influenza vaccination of healthy children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Antivirals and antibiotics for influenza in the United States, 1995--2002

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Short-term outcomes after acute treatment of pediatric asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Utility scores for chronic conditions in a community-dwelling population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Developing a center for comparative effectiveness information

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

When Is Evidence Sufficient?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003-2004.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.046

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.03.046

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44276981&oldid=2109082591"